Oveporexton (TAK-861)
Cognitive · Orexin receptor 2 (OX2R) agonist / wakefulness
Tier B
Bottom line
Read Off Label grades Oveporexton (TAK-861) as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.
The wakefulness frontier's biggest swing — Takeda's orexin agonist restores the exact signal narcolepsy patients lack instead of stimulating broadly like amphetamine or modafinil.
Studied, labeled, or reported-use context: Oral tablet twice daily (Phase 3 studied 1 mg and 2 mg twice daily) — Rx; not individualized guidance.
What the evidence says
The wakefulness frontier's biggest swing — Takeda's orexin agonist restores the exact signal narcolepsy patients lack instead of stimulating broadly like amphetamine or modafinil. Phase 3 FirstLight and RadiantLight (NT1, ~270+ patients) met all primary and secondary endpoints, with ~80% reduction in weekly cataplexy and large daytime-sleepiness improvements; >95% of participants continued into the long-term extension. If cleared it is approved only for narcolepsy, but it proves orexin agonism works in humans — opening the door to broader wakefulness/cognitive uses. FDA Priority Review, PDUFA Q3 2026. Industry-sponsored; pivotal peer-reviewed publication pending. **FDA approved 5 Aug 2026 as ORZEYFUL (oveporexton) for narcolepsy type 1 in adults** — the first approved orexin receptor agonist and the first therapy aimed at the underlying orexin deficiency rather than at symptoms. Approval rested on the two 12-week randomized, double-blind, placebo-controlled Phase 3 studies (FirstLight and RadiantLight, 273 adults), which improved excessive daytime sleepiness, cataplexy and quality of life. Label adverse events are frequent though not serious: insomnia 55-60% and urinary frequency 53-58% versus 1% and 5% on placebo. DEA scheduling is still pending. The approval is narcolepsy-only, but it is the first proof in humans that orexin agonism works — the reason this row matters beyond sleep medicine. Off-label wakefulness or cognitive use in people without narcolepsy remains completely untested.
Mechanism
First-in-class oral orexin-2 receptor-selective agonist; directly replaces the orexin signaling lost in narcolepsy type 1 to drive wakefulness and suppress cataplexy — a mechanism distinct from amphetamines and modafinil
Studied, labeled, or reported dose & route
Oral tablet twice daily (Phase 3 studied 1 mg and 2 mg twice daily)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Oveporexton (TAK-861)'s effects?
- Read Off Label rates the evidence for Oveporexton (TAK-861) as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). The wakefulness frontier's biggest swing — Takeda's orexin agonist restores the exact signal narcolepsy patients lack instead of stimulating broadly like amphetamine or modafinil.
- What safety findings are reported for Oveporexton (TAK-861)?
- Oveporexton (TAK-861) has a med risk profile in the database. Med (label adverse events common but non-serious: insomnia 55-60% vs 1% placebo, urinary frequency 53-58% vs 5%, urinary urgency ~15% vs 1%, excessive salivation; earlier orexin-agonist hepatotoxicity not seen with this agent; long-term unknown) Legal status: Rx (FDA approved 5 Aug 2026 as ORZEYFUL for narcolepsy type 1 in adults; DEA controlled-substance scheduling pending, expected within 90 days of approval).
- What doses or routes are reported for Oveporexton (TAK-861)?
- Oral tablet twice daily (Phase 3 studied 1 mg and 2 mg twice daily) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Oveporexton (TAK-861) work?
- First-in-class oral orexin-2 receptor-selective agonist; directly replaces the orexin signaling lost in narcolepsy type 1 to drive wakefulness and suppress cataplexy — a mechanism distinct from amphetamines and modafinil
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.